Standard Chartered has introduced direct Bitcoin and Ethereum trading for its affluent clients in the UAE, allowing them to buy and sell these cryptocurrencies through their existing bank accounts. This service operates under Dubai's Virtual Assets Regulatory Authority license and uses a closed-loop system for custody and settlement, reducing third-party risks. The offering marks a global first for Standard Chartered and aims to expand to other markets in the future. Previously, crypto access was indirect via ETFs and derivatives, but now clients can directly own the coins held by the bank.
Standard Chartered's new Bitcoin and Ethereum trading service for wealthy UAE clients is introduced as context. For readers following the cryptocurrency market, here is Pluang's market snapshot as of Oct 15, 2026 00:11 WIB: out of 50 major cryptocurrencies, 6 rose and 43 fell today. Notable movers include THETA at Rp3.535 with a 1-day change of -4.15% and 100% buy order activity, EGLD at Rp65.162 down 4.11% with 58% buy orders, and ATOM at Rp31.507 down 4.10% with 80% buy orders and a typical hold time of 61 days.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
